Frederick L. Locke

31.9k total citations · 3 hit papers
307 papers, 6.0k citations indexed

About

Frederick L. Locke is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Frederick L. Locke has authored 307 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 259 papers in Oncology, 90 papers in Immunology and 69 papers in Pathology and Forensic Medicine. Recurrent topics in Frederick L. Locke's work include CAR-T cell therapy research (245 papers), Lymphoma Diagnosis and Treatment (68 papers) and Biosimilars and Bioanalytical Methods (53 papers). Frederick L. Locke is often cited by papers focused on CAR-T cell therapy research (245 papers), Lymphoma Diagnosis and Treatment (68 papers) and Biosimilars and Bioanalytical Methods (53 papers). Frederick L. Locke collaborates with scholars based in United States, France and Germany. Frederick L. Locke's co-authors include Sattva S. Neelapu, Yi Lin, Jason R. Westin, Partow Kebriaei, Katayoun Rezvani, Nitin Jain, William G. Wierda, Alison Gulbis, Sherry Adkins and Elizabeth J. Shpall and has published in prestigious journals such as Circulation, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Frederick L. Locke

274 papers receiving 5.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations Sattva S. Neelapu, Partow Kebriaei et al. profile →
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. profile →
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

2024 132 citations Marcelo C. Pasquini, Marcela V. Maus et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Frederick L. Locke	5.2k	1.4k	1.4k	1.2k	1.2k	307	6.0k
Vanessa Gonzalez	5.0k 1.0×	1.5k 1.0×	1.8k 1.3×	719 0.6×	1.4k 1.2×	20	5.6k
Constance M. Yuan	4.2k 0.8×	1.5k 1.0×	1.7k 1.2×	591 0.5×	996 0.9×	121	5.9k
Sindhu Cherian	3.0k 0.6×	853 0.6×	834 0.6×	614 0.5×	785 0.7×	59	3.8k
Shannon L. Maude	7.7k 1.5×	2.1k 1.5×	2.5k 1.9×	1.1k 0.9×	1.9k 1.7×	107	9.2k
Craig S. Sauter	3.4k 0.7×	777 0.6×	973 0.7×	542 0.4×	689 0.6×	189	4.7k
Jason R. Westin	4.5k 0.9×	1.1k 0.8×	1.1k 0.8×	776 0.6×	751 0.6×	224	6.0k
Anne Chew	8.4k 1.6×	2.5k 1.8×	3.3k 2.4×	1.1k 0.9×	2.3k 2.0×	34	9.6k
Marco Ruella	3.2k 0.6×	1.3k 0.9×	1.3k 1.0×	385 0.3×	809 0.7×	124	4.0k
Claudia Rössig	4.4k 0.8×	1.4k 1.0×	2.4k 1.8×	355 0.3×	951 0.8×	157	5.8k
Lihua E. Budde	3.0k 0.6×	734 0.5×	917 0.7×	390 0.3×	530 0.5×	160	3.4k

Countries citing papers authored by Frederick L. Locke

Since Specialization

Citations

This map shows the geographic impact of Frederick L. Locke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick L. Locke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick L. Locke more than expected).

Fields of papers citing papers by Frederick L. Locke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick L. Locke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick L. Locke. The network helps show where Frederick L. Locke may publish in the future.

Co-authorship network of co-authors of Frederick L. Locke

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick L. Locke. A scholar is included among the top collaborators of Frederick L. Locke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick L. Locke. Frederick L. Locke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naderinezhad, Samira, et al.. (2025). Humanin-like 8 regulates metabolic fitness and anti-apoptotic programming in CD19 CAR-T cells. Blood. 146(Supplement 1). 5906–5906.

Locke, Frederick L., Jason R. Westin, & Christina To. (2025). Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphoma. Future Oncology. 21(4). 393–407.

Locke, Frederick L., Zahra Mahmoudjafari, Partow Kebriaei, et al.. (2025). Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. Transplantation and Cellular Therapy. 31(6). 349.e1–349.e12. 3 indexed citations

Balagurunathan, Yoganand, Jin Qi, Zachary Thompson, et al.. (2024). Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy. Frontiers in Oncology. 14. 1485039–1485039. 2 indexed citations

Bhaskar, Shakthi, Babatunde Adedokun, Olalekan O. Oluwole, et al.. (2024). Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report. Blood. 144(Supplement 1). 527–527. 2 indexed citations

Díaz, Juan Manuel Mancilla, Saurabh Dahiya, Maeve O’Reilly, et al.. (2024). Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies. Blood. 144(Supplement 1). 7239–7239.

Locke, Frederick L., Sattva S. Neelapu, Nancy L. Bartlett, et al.. (2024). Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 30(11). 1065–1079. 13 indexed citations

Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2024). Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Advances. 8(11). 2982–2990. 4 indexed citations

Punekar, Salman R., J. Randolph Hecht, Diane M. Simeone, et al.. (2024). EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).. Journal of Clinical Oncology. 42(16_suppl). TPS2699–TPS2699. 5 indexed citations

10.

Rejeski, Kai, Yucai Wang, Doris K. Hansen, et al.. (2024). Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Advances. 8(8). 1857–1868. 29 indexed citations

11.

Oluwole, Olalekan O., M. D. Ray, Keith Chan, et al.. (2023). 838P Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+). Annals of Oncology. 34. S548–S548. 3 indexed citations

12.

Fernandez, Mario R., Chunying Yang, Lancia Darville, et al.. (2023). Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 8(18). 15 indexed citations

13.

Freeman, Ciara L., Meghan Menges, Hien Liu, et al.. (2023). Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines. Blood. 142(Supplement 1). 1931–1931. 1 indexed citations

14.

Rejeski, Kai, Doris K. Hansen, Yucai Wang, et al.. (2023). Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality. Blood. 142(Supplement 1). 359–359. 1 indexed citations

15.

Locke, Frederick L., et al.. (2023). Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy. Hematology/Oncology Clinics of North America. 37(6). 1189–1199. 2 indexed citations

16.

Choi, Jung Woo, Erin Dean, Hong Lu, et al.. (2023). Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers. Frontiers in Immunology. 14. 994520–994520. 5 indexed citations

17.

Barata, Anna, Aasha I. Hoogland, Kelly A. Hyland, et al.. (2021). Patient-Reported Toxicities in Axicabtagene Ciloleucel Recipients: 1-Year Follow-up. Transplantation and Cellular Therapy. 27(3). S375–S375. 1 indexed citations

18.

Lee, Dae Hyun, Sanjay Chandrasekhar, Michael D. Jain, et al.. (2021). Abstract 9828: Active Surveillance of Cardiotoxicity with Cardiac Biomarkers During Chimeric Antigen Receptor T-Cell Therapy. Circulation. 144(Suppl_1). 2 indexed citations

19.

Perez, Ariel Perez, Christina A. Bachmeier, Aleksandr Lazaryan, et al.. (2020). Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel. Blood. 136(Supplement 1). 4–5. 3 indexed citations

20.

Pasquini, Marcelo C., Frederick L. Locke, Alex F. Herrera, et al.. (2019). Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood. 134(Supplement_1). 764–764. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact